GD-SILDENAFIL TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

SILDENAFIL (SILDENAFIL CITRATE)

Prieinama:

GENMED A DIVISION OF PFIZER CANADA ULC

ATC kodas:

G04BE03

INN (Tarptautinis Pavadinimas):

SILDENAFIL

Dozė:

50MG

Vaisto forma:

TABLET

Sudėtis:

SILDENAFIL (SILDENAFIL CITRATE) 50MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

4/8

Recepto tipas:

Prescription

Gydymo sritis:

PHOSPHODIESTERASE TYPE 5 INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0136261002; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2015-08-03

Prekės savybės

_ _
_GD-SILDENAFIL* (sildenafil citrate) Product Monograph _
_Page 1 of 49 _
PRODUCT MONOGRAPH
GD-SILDENAFIL *
sildenafil as sildenafil citrate
Tablets 25 mg, 50 mg and 100 mg
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
Submission Control No: 193905
GenMed, a division of Pfizer Canada Inc.
17,300 TranCanada Highway
Kirkland, Quebec H9J 2M5
*TM Pfizer Canada Inc.
GenMed, a division of Pfizer Canada Inc., Licensee
Date of Preparation:
6 May 2016
_ _
_GD-SILDENAFIL* (sildenafil citrate) Product Monograph _
_Page 2 of 49 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................21
SPECIAL HANDLING INSTRUCTIONS
.......................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL INFORMATION
...............................